Cesare Miranda, Elena Garlatti, Andrea Da Porto, Elena Rinaldo, Silvia Grazioli, Giorgio Zanette, Maurizio Tonizzo
{"title":"COVID-19合并非酒精性脂肪性肝病患者的肝损伤:最新进展","authors":"Cesare Miranda, Elena Garlatti, Andrea Da Porto, Elena Rinaldo, Silvia Grazioli, Giorgio Zanette, Maurizio Tonizzo","doi":"10.5114/amsad/160950","DOIUrl":null,"url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.</p>","PeriodicalId":8317,"journal":{"name":"Archives of Medical Sciences. Atherosclerotic Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/4f/AMS-AD-8-160950.PMC10161789.pdf","citationCount":"3","resultStr":"{\"title\":\"Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update.\",\"authors\":\"Cesare Miranda, Elena Garlatti, Andrea Da Porto, Elena Rinaldo, Silvia Grazioli, Giorgio Zanette, Maurizio Tonizzo\",\"doi\":\"10.5114/amsad/160950\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.</p>\",\"PeriodicalId\":8317,\"journal\":{\"name\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/4f/AMS-AD-8-160950.PMC10161789.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/amsad/160950\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Sciences. Atherosclerotic Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/amsad/160950","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update.
The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.